Vanguard Group Inc. Cuts Stock Holdings in USANA Health Sciences, Inc. $USNA

Vanguard Group Inc. reduced its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 11.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,373,908 shares of the company’s stock after selling 172,782 shares during the period. Vanguard Group Inc. owned approximately 7.38% of USANA Health Sciences worth $37,054,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its holdings in USANA Health Sciences by 339.6% during the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company’s stock worth $27,000 after purchasing an additional 771 shares in the last quarter. Versant Capital Management Inc raised its holdings in USANA Health Sciences by 542.5% during the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company’s stock worth $31,000 after purchasing an additional 971 shares in the last quarter. Parallel Advisors LLC raised its holdings in USANA Health Sciences by 8,141.2% during the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company’s stock worth $38,000 after purchasing an additional 1,384 shares in the last quarter. US Bancorp DE increased its holdings in USANA Health Sciences by 13.1% in the first quarter. US Bancorp DE now owns 4,611 shares of the company’s stock valued at $124,000 after buying an additional 535 shares in the last quarter. Finally, Public Employees Retirement System of Ohio increased its holdings in USANA Health Sciences by 635.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 5,075 shares of the company’s stock valued at $182,000 after buying an additional 4,385 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider David Mulham Mulham sold 3,515 shares of the firm’s stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilbert A. Fuller sold 1,058 shares of the firm’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,073 shares of company stock worth $151,982. 0.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.00.

USANA Health Sciences Price Performance

Shares of USNA opened at $31.71 on Wednesday. The firm has a 50 day simple moving average of $31.05 and a 200-day simple moving average of $29.56. USANA Health Sciences, Inc. has a 1-year low of $23.10 and a 1-year high of $41.83. The stock has a market cap of $579.38 million, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 1.01 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The business had revenue of $235.85 million during the quarter, compared to analysts’ expectations of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. On average, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.